FDA fast tracks psychedelic drugs for mental health

Reading

Read this text and listen to it at the same time. If you don’t know a word click it to see explanation, hear pronunciation or add it to vocabulary.

The FDA will quickly review three psychedelic drugs. These drugs may help people with mental health problems.

Two companies are studying psilocybin for depression. Another company uses a different drug for PTSD.

Special vouchers help speed up these drug reviews. The FDA wants to evaluate new treatments with urgency.

The FDA also allowed testing for a drug related to ibogaine. Research for this type of drug faced funding problems before.

Many psychedelic drugs are currently illegal to use. But now, many companies want FDA approval for them.

Answer the questions to the text. Speak or write, you choose. AI will assess your answers.

What will the FDA review?

The FDA will quickly review three psychedelic drugs.

What mental health problems are being studied?

Psilocybin is being studied for depression and another drug is being used for PTSD.

Why does the FDA want to evaluate new treatments quickly?

The FDA wants to evaluate new treatments with urgency.

Look at the article image and describe what you see on it. You may either speak or write your answer there.

Discuss this article with your AI tutor to practice. Your tutor will help you with vocabulary and grammar.

Read a new article every day and
discuss it with AI at lingolette.com